US-based Adaptyx Biosciences has secured $14m to scale its bio-wearable that translates molecular data into actionable healthcare insights.
Bringing the clinical stage company’s total funding to around $23m, the seed financing round was led by Los Angeles-based tech investment company Interlagos, with participation from entities such as Overwater Ventures and Stanford University.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Adaptyx’s bio-wearable is a skin patch with a minimally invasive dermal probe that monitors biomarkers in interstitial fluid.
The platform underpinning the patch tracks human biochemistry, including small molecules, electrolytes, and hormones. According to Adaptyx, through continuous molecular sensing paired with AI-powered analytics, the platform translates data into actionable insights, to enable the earlier detection of concerning health trends and the ability for interventional action to be taken before emergent issues escalate.
Adaptyx’s CEO Vijit Sabnis said healthcare currently suffers from a “data deficit”. Laboratory tests only provide “snapshots” of health that don’t account for the body’s changing physiology, thereby resulting in blind spots that “prevent addressing many of today’s health challenges”.
Sabnis added: “Our mission is to expand continuous monitoring beyond glucose to include the many molecules that drive human health, creating a rich data pipeline that guides patients and clinicians to make the best decisions at the right time.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataKnown as Molecular Switch Foundry, Adaptyx’s proprietary technology facilitates tracking human biochemistry via programmable molecular switches. The laboratory-developed DNA bioreceptors are designed to bind target molecules with high sensitivity and specificity to enable the continuous monitoring of diverse biomarkers.
According to Adaptyx, its technology accelerates biosensor development by integrating automated molecular design, parallelised screening, and AI‑driven optimisation that compresses development timelines “from years to weeks”.
Adaptyx’s chief science officer Alex Yoshikawa explained: “Each new switch generates structured datasets that make the system smarter and faster, rapidly expanding the analyte library and powering new applications.”
Current applications in development include heart failure management and hormone optimisation. Adaptyx’s platform monitors cardiac biomarkers and detects abnormalities early – enabling intervention before decompensation occurs. It also provides continuous hormone and metabolite profiling to support the management of endocrine health, including metabolic disorders and fertility care.
Adaptyx’s co-founder and scientific adviser Professor Tom Soh commented: “After 17 years of developing this technology in academia, we’re ready to bring continuous molecular monitoring from the lab to real patients.
“The ability to continuously track multiple biomarkers simultaneously is a breakthrough that will transform how we understand human health and improve care for everyone.”
